The goal of the study was to examine if the treatment remained effective in minimizing NAO symptoms due to nasal valve collapse two years later, after proving successful in three-month, six-month and one-year follow ups, according to a July 13 news release from Aerin Medical.
The findings revealed that the technology was successful in improving symptoms in 90.1 percent of patients after two years, corresponding to a 57 percent improvement overall.
VivAer is a stylus that is inserted into the nostril and uses patented, temperature-controlled radiofrequency energy to alter the nasal tissue and improve airflow.
